Meclofenoxate

From WikiMD's WELLNESSPEDIA

Meclofenoxate.svg

Nootropic drug

Meclofenoxate



Trade names Lucidril


Chemical nomenclature
IUPAC name 2-(dimethylamino)ethyl 4-chlorophenoxyacetate



Routes Oral







Identifiers
CAS Number 51-68-3
PubChem 4054
DrugBank DB08991
ChemSpider 3915
UNII 6VC9M9D5AM
KEGG D05029
ChEMBL 1201321
Chemical data
Chemical formula C12H16ClNO3







Meclofenoxate, also known as centrophenoxine, is a nootropic drug used to improve cognitive function and treat symptoms of senile dementia and Alzheimer's disease. It is marketed under the brand name Lucidril.

Mechanism of Action[edit]

Meclofenoxate is an ester of dimethylaminoethanol (DMAE) and p-chlorophenoxyacetic acid (pCPA). It is believed to work by increasing the levels of acetylcholine in the brain, a neurotransmitter associated with memory and learning. Additionally, it may enhance the uptake of glucose and oxygen by the brain, thereby improving neuronal energy metabolism.

Uses[edit]

Meclofenoxate is primarily used in the treatment of cognitive disorders such as senile dementia and Alzheimer's disease. It is also used as a nootropic to enhance memory, learning, and overall cognitive function in healthy individuals.

Side Effects[edit]

Common side effects of meclofenoxate include nausea, gastrointestinal discomfort, and insomnia. In rare cases, it may cause allergic reactions or hypertension.

Dosage[edit]

The typical dosage of meclofenoxate varies depending on the condition being treated. For cognitive enhancement, doses range from 250 mg to 1000 mg per day, divided into two or three doses. For the treatment of dementia, higher doses may be required, as prescribed by a healthcare provider.

History[edit]

Meclofenoxate was first developed in the 1950s and has been used in various countries for the treatment of cognitive disorders. It has gained popularity as a nootropic in recent years due to its potential cognitive-enhancing effects.

See Also[edit]

References[edit]


Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Meclofenoxate&oldid=5808616"